These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11313006)

  • 1. The immunology of Epstein-Barr virus infection.
    Moss DJ; Burrows SR; Silins SL; Misko I; Khanna R
    Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):475-88. PubMed ID: 11313006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
    Delecluse HJ; Feederle R; Behrends U; Mautner J
    Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire.
    D'Orsogna LJ; Amir AL; Zoet YM; van der Meer-Prins PM; van der Slik AR; Kester MG; Heemskerk MH; Doxiadis II; Roelen DL; Claas FH
    Tissue Antigens; 2009 Oct; 74(4):290-7. PubMed ID: 19624615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus and systemic lupus erythematosus.
    James JA; Harley JB; Scofield RH
    Curr Opin Rheumatol; 2006 Sep; 18(5):462-7. PubMed ID: 16896283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human T cell immune response to Epstein-Barr virus.
    Landais E; Saulquin X; Houssaint E
    Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with virus-specific cytotoxic T lymphocytes after organ transplantation.
    Lucas KG; Sun Q
    Pediatr Transplant; 2006 Mar; 10(2):142-4. PubMed ID: 16573596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell memory: lessons from Epstein-Barr virus infection in man.
    Rickinson AB; Callan MF; Annels NE
    Philos Trans R Soc Lond B Biol Sci; 2000 Mar; 355(1395):391-400. PubMed ID: 10794060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
    Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
    Turcanová V; Höllsberg P
    J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of antigen and fine peptide specificity of EBV-specific CTLs.
    Levitsky V; Frisan T; Masucci M
    Methods Mol Biol; 2001; 174():209-11. PubMed ID: 11357646
    [No Abstract]   [Full Text] [Related]  

  • 15. Limiting dilution assay.
    Frisan T; Levitsky V; Masucci M
    Methods Mol Biol; 2001; 174():213-6. PubMed ID: 11357647
    [No Abstract]   [Full Text] [Related]  

  • 16. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
    Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
    J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hodgkin's disease and Epstein-Barr virus].
    Depil S; Moralès O; Auriault C
    Ann Biol Clin (Paris); 2004; 62(6):639-48. PubMed ID: 15563422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biology of Epstein-Barr virus: lessons learned from the virus and the host.
    Cohen JI
    Curr Opin Immunol; 1999 Aug; 11(4):365-70. PubMed ID: 10448133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
    Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
    AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.